SCIENTIFIC REPORT 2010 - 2011 - IOV

a new approach to an old question. Urologic Oncology: Seminars and
Original Investigations; 28:4; 377-388; 2010
77 Golfieri R, Pescarini L, Fileni A, Silverio R, Saccavini C, Visconti D,
Morana G, Centonze,M. Clinical Risk Management in radiology.
Part I: general background and types of error and their prevention.
Radiologia medica; 115:7; 1121-1146; 2010
78 Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J,
Frauendorfer K, Niederwieser D, EBMT WG [as collab. Aversa Savina
M L, Marino D, Jirillo A, Canova F, Trentin C]. The EBMT activity
survey 2008: impact of team size, team density and new trends. Bone
marrow transplantation; 46; 2; 174-191; 2011 (E-pub 2010)
79 Greco M T, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone
G. On behalf of the Writing Protocol Committee and the Cancer
Pain Outcome Research Study Group (CPOR SG) Investigators;
Epidemiology and Pattern of Care of Breakthrough Cancer Pain in
a Longitudinal Sample of Cancer Patients: Results From the Cancer
Pain Outcome Research Study Group. The Clinical journal of pain;
27-1; 9-18; 2011 (E-pub 2010)
80 Grohmann U, Bronte V. Control of immune response by amino acid
metabolism. Immunological reviews; 236:1; 243-264; 2010
81 Gusella M, Pasini F, Bolzonella C, Meneghetti S, Barile C, Bononi
A, Toso C, Menon D, Crepaldi G, Modena Y, Stievano L, Padrini R.
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase
activity and age predict gemcitabine plasma clearance in patients
with solid tumors. British Journal of Clinical Pharmacology; 71:3;
437-434; 2011 (E-pub 2010)
82 HAEMACARE W G [as collab. Zambon P]. Manual for coding and
reporting haematological malignancies. Tumori; 96:4; i-A32; 2010
83 Hsu W-M, Carraro A, Kulig K M, Miller M L, Kaazempur-Mofrad
M, Weinberg E, Entabi F, Albadawi H, Watkins M T, Borenstein J T,
Vacanti J P, Neville C. Liver-assist device with a microfluidics-based
vascular bed in an animal model. Annals of Surgery; 252:2; 351-357;
2010
84 Indraccolo S. Interferon-α as angiogenesis inhibitor: learning from
tumor models. Autoimmunity; 43:3; 244-247; 2010
85 Indraccolo S, Minuzzo S, Masiero M, Amadori A. Ligand-driven
activation of the notch pathway in T-ALL and solid tumors: Why
Not(ch)? Cell cycle; 9:1; 80-85; 2010
86 International Prognostic Factors Study Group, Lorch A, Beyer J,
Bascoul-Mollevi C, Kramar A, Einhorn L H, Necchi A, Massard C, De
Giorgi U, Flechon A, Margolin K A, Lotz J P, Germa Lluch J R, Powles
PUBLICATIONS
284
T, Kollmannsberger C K, [as collab. Basso U]. Prognostic factors in
patients with metastatic germ cell tumors who experienced treatment
failure with cisplatin-based first-line chemotherapy. Journal of
Clinical Oncology; 28:33; 4906-4911; 2010
87 Jirillo A, Vascon F. New rules on conflict of interest: what has to be
done in Europe? Tumori; 96:1; 180-181; 2010
88 Koussis H, Maruzzo M, Scola A, Ide Casal E, Fassina A, Marioni
G, Lora O, Corti L, Karachontziti P, Jirillo A. A Case of Anaplastic
Thyroid Cancer with Long-term Survival. Anticancer Research; 30:4;
1273-1278; 2010
89 Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, Aglietta
M, Lonardi S, Corsi D, Turci D, Beretta G D, Fornarini G, Dapretto
E, Floriani I, Zaniboni A, on behalf of Italian Group for the Study
of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous
chemotherapy in advanced colorectal cancer: a randomised
‘GISCAD’ trial. Annals of Oncology; 22:5; 1236-1242; 2010
90 Lombardi G, Zustovich F, Della Puppa A, Borgato L, Orvieto E, Manara
R, Cecchin D, Berti F, Farina P, Gardiman M P, Scienza R, Zagonel
V. Cisplatin and temozolomide combination in the treatment of
leptomeningeal carcinomatosis from ethmoid sinus intestinal-type
adenocarcinoma. Journal of neuro-oncology; 104:1; 381-386; 2010
91 Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto M O,
Pastorelli D. An update on targeted therapy in metastatic renal cell.
carcinoma; Urologic Oncology; E-pub; 2010 E-pub
92 Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus
G, Donach M, Farina M, Zovato S, Pastorelli D. Pegylated
liposomal doxorubicin and gemcitabine in patients with advanced
hepatocellular carcinoma: Results of a phase 2 study. Cancer; 117:1;
125-133; 2011 (E-pub 2010)
93 Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia L J, Munoz
I, Schiavi F, Montero-Conde C, De Cubas Aguirre A, RamiresR,
Landa I, Leskela S, Maliszewska A, Inglada-Perez L, De la Vega L,
Rodriguez-Antona C, Leton R, Bernal C, De Campos J M, Diez-
Tascon C, Fraga M F, Boullosa C, Pisano D G, Opocher G, Robledo
M, Cascon A. Research Resource: Transcriptional Profiling Reveals
Different Pseudohypoxic Signatures in SDHB and VHL-Related
Pheochromocytomas. Molecular Endocrinology; 24:12; 2382-2391;
2010
94 Lumachi F, Frigo A C, Basso U, Tombolan V, Ermani M. Estrogen
therapy and risk of breast cancer in postmenopausal women: a
case-control study and results of a multivariate analysis. Menopause;